A Phase 4 interventional study of testosterone and placebo in Hypogonadism, sponsored by University at Buffalo. Completed at 1 site in United States. Open to male participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-11-29.
Sponsored by University at Buffalo · Phase 4, Interventional, and Treatment
The purpose of this study is to examine the effect of having testosterone deficiency in men with diabetes and with obesity. The study will also evaluate the effect of testosterone therapy. This will be done by comparing the changes in several body response indicators following treatment with testosterone in diabetic or obese-non diabetic men with low testosterone levels and comparing them to diabetic or obese-non diabetic men with low testosterone who are not treated with testosterone.
Hypogonadotropic hypogonadism (HH) occurs in approximately one-third of obese and type 2 diabetic men. Considering that there are 24 million diabetic and 100 million obese people, of which half are males, obesity and type 2 diabetes potentially constitute the major cause of hypogonadism in the population. We hypothesize that 1) HH in obese and type 2 diabetic men is associated with decreased insulin sensitivity, increased fat tissue mass, decreased lean body mass, increased inflammatory and oxidative stress, impaired sexual function and depressed mood as compared to diabetic and obese men with normal testosterone concentrations; and that 2) testosterone replacement for 24 weeks in men with HH leads to an improvement in these parameters. Our proposed study would be the first prospective, randomized trial to comprehensively evaluate the effect of HH on insulin sensitivity, body composition, inflammatory and oxidative indices in obese and type 2 diabetic subjects and the effect of six months of T replacement on these parameters. The study will have 2 arms (obese and type 2 diabetic arm) with 120 subjects in Diabetes arm and 80 subjects in obese arm. Half of men in each arm will have HH and half men will have normal testosterone concentrations(eugonadal men). Insulin sensitivity will be assessed by hyperinsulinemic-euglycemic clamps. Subcutaneous fat mass and lean body mass will be measured by DEXA and intra-abdominal (visceral) fat mass by MRI. All subjects will undergo hyperinsulinemic-euglycemic clamp, MRI, DEXA and give blood and urine samples (for measurement of inflammatory and oxidative stress) at baseline. Men with HH will then be randomized to receive testosterone or placebo gel for a total of 24 weeks. These men will undergo hyperinsulinemic-euglycemic clamps and give blood and urine samples for inflammation and oxidative stress at 4 weeks and 24 weeks. MRI and DEXA examinations will be carried out at 24 weeks again in men with HH. The primary endpoint of the study is to define a difference in whole body glucose uptake during hyperinsulinemic-euglycemic clamps between hypogonadal and eugonadal diabetes patients at baseline and an increase in glucose uptake in HH subjects after treatment with testosterone for 24 weeks. 30 subjects per group(testosterone and placebo gel each) will provide adequate power (0.8) to detect a significant difference of 10% in whole body glucose uptake. Therefore there will be 60 men with HH in each arm in diabetes group. For baseline comparisons, 60 men with normal testosterone concentrations will also be needed in each arm. We will recruit 40 obese patients in each arm. Thus there will be 120 diabetic men and 80 obese men in the study.
345 studies on the registry are indexed under Hypogonadism; 43 are open to participants now.
This study's enrollment of 137 is above the median of 56 across 260 interventional studies indexed under Hypogonadism.
Browse Hypogonadism studies →University at Buffalo is the lead sponsor of 73 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
1)Coronary event or procedure(myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous twelve weeks; 2) PSA > 4ng/ml; 3)Hemoglobin A1c > 8%; 4)h/o prostate carcinoma; 5)Hepatic disease (transaminase > 3 times normal) or cirrhosis; 6)Renal impairment (defined as GFR\<30); 7)HIV or Hepatitis C positive status; 9)Participation in any other concurrent clinical trial; 10)Any other life-threatening, non-cardiac disease; 11)Use of over the counter health supplements which contain androgens; 12)Use of an investigational agent or therapeutic regimen within 30 days of study; 13)prostate nodule or severe enlargement on digital rectal examination; 14)Use of testosterone currently or in the past 4 months; 15)Hematocrit > 50%; 16)History of untreated severe obstructive sleep apnea(defined as apnea-hypopnea index ≥30); 17)symptoms suggestive of severe BPH; 18)Congestive heart failure, class III or IV; 20)Known to have anemia secondary to iron, B12 or folic acid deficiency; 21)bone marrow disorder such as myelodysplasia or aplastic anemia; 22) currently suffering from symptomatic depression, with or without treatment; 23) history of severe depression in the past which needed hospitalization; 24)currently suffering from foot ulcer, significant periodontal disease or any other chronic infectious condition; 25)planning to have children. 26) Subjects on testosterone or with testosterone replacement in the past 4 months will be excluded.
Subjects with diabetes and hypogonadotropic hypogonadism. They will be randomized to testosterone intervention.
Drug: testosterone
Eugonadal subjects with diabetes. They will not be treated
Obese non-diabetic men hypogonadotropic hypogonadism. They will be randomized to testosterone intervention.
Drug: testosterone
Eugonadal non-diabetic obese subjects. They will not be treated
Subjects with diabetes and hypogonadotropic hypogonadism. They will be randomized to placebo.
Drug: placebo
Obese non-diabetic men hypogonadotropic hypogonadism. They will be randomized to placebo.
Drug: placebo
intramuscular every 2 weeks
saline intramuscular every 2 weeks
Insulin Sensitivity
measured by HE clamps (baseline and 6 mths)
Time frame: baseline to 6 months
Body Composition
Body composition using Total body fat mass (kg)
Time frame: baseline to 6 months
| Milestone | Diabetes With HH: Testosterone | Diabetes With HH: Placebo | Obese Testosterone | Obese Placebo | Eugonadal Diabetes | Eugonadal Obese |
|---|---|---|---|---|---|---|
| Started | 22 | 22 | 12 | 10 | 50 | 21 |
| Completed | 20 | 14 | 10 | 6 | 50 | 21 |
| Not completed | 2 | 8 | 2 | 4 | 0 | 0 |
measured by HE clamps (baseline and 6 mths)
| mg/kg fat free mass/min | Diabetes With HH: Testosterone | Diabetes With HH: Placebo | Obese With HH: Testosterone | Obese With HH: Placebo | Eugonadal Diabetes | Eugonadal Obese |
|---|---|---|---|---|---|---|
| baseline | 6.66 ± 4.36 | 5.12 ± 2.79 | 11.37 ± 8.83 | 12.93 ± 5.16 | 10.29 ± 5.55 | 12.30 ± 5.96 |
| 6 months | 8.73 ± 4.27 | 5.06 ± 3.62 | 12.96 ± 7.11 | 14.57 ± 1.71 | — | — |
Body composition using Total body fat mass (kg)
| kg | Diabetes With HH: Testosterone | Diabetes With HH: Placebo | Obese Testosterone | Obese Placebo | Eugonadal Diabetes | Eugonadal Obese |
|---|---|---|---|---|---|---|
| Baseline | 44.5 ± 13.7 | 44.5 ± 15.0 | 50.2 ± 9.5 | 48.8 ± 10.4 | 34.0 ± 12.0 | 40.2 ± 12.4 |
| 24 WEEKS | 42.1 ± 12.5 | 45.4 ± 14.4 | 46.4 ± 11.7 | 48.4 ± 11.2 | — | — |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Diabetes With HH: Testosterone | — | 0/22 (0%) | 0/22 (0%) |
| Diabetes With HH: Placebo | — | 0/22 (0%) | 0/22 (0%) |
| Obese With HH: Testosterone | — | 0/12 (0%) | 0/12 (0%) |
| Obese With HH: Placebo | — | 0/10 (0%) | 0/10 (0%) |
| Eugonadal Diabetes | — | 0/50 (0%) | 0/50 (0%) |
| Eugonadal Obese | — | 0/21 (0%) | 0/21 (0%) |
| Age, Categorical(Participants) | Diabetes With HH: Testosterone | Obese With HH: Testosterone | Obese With HH: Placebo | Diabetes With HH: Placebo | Eugonadal Diabetes | Eugonadal Obese | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 22 | 12 | 10 | 22 | 50 | 21 | 137 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Diabetes With HH: Testosterone | Obese With HH: Testosterone | Obese With HH: Placebo | Diabetes With HH: Placebo | Eugonadal Diabetes | Eugonadal Obese | Total |
|---|---|---|---|---|---|---|---|
| Mean | 54 ± 7 | 46 ± 9 | 53 ± 7 | 54 ± 9 | 52 ± 9 | 50 ± 8 | 52 ± 8 |
| Sex: Female, Male(Participants) | Diabetes With HH: Testosterone | Obese With HH: Testosterone | Obese With HH: Placebo | Diabetes With HH: Placebo | Eugonadal Diabetes | Eugonadal Obese | Total |
|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 22 | 12 | 10 | 22 | 50 | 21 | 137 |
| Region of Enrollment(participants) | Diabetes With HH: Testosterone | Obese With HH: Testosterone | Obese With HH: Placebo | Diabetes With HH: Placebo | Eugonadal Diabetes | Eugonadal Obese | Total |
|---|---|---|---|---|---|---|---|
| United States | 22 | 12 | 10 | 22 | 50 | 21 | 137 |
Plan to share: No
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University at Buffalo